Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected
Comparing 2 of 2 drugs
× ×
Change selection
2 drug columns · use arrows or scrollbar
Field CLOPIDOGREL
Haematology · Haematology · Level 2
ABCIXIMAB
Haematology · Haematology · Level 3
Mechanism of action

Prodrug. Hepatic activation to active agent (Thiol derivative, by oxidation and hydrolysis) which is an ADP receptor antagonist
- Irreversible inhibition of P2Y12 receptor at platelet surface → Inhibits activation of GPIIb/IIIa → Inhibits platelet activation

Similar mechanism as tirofiban but monoclonal
antibody

Absorption

- PO. BA 50%
- 600mg loading. 75mg maint.

—
Protein binding

95% protein binding,

—
Volume of distribution

Vd unknown

—
Metabolism

- Hepatic CYP450 2C19 + Esterases to Inactive metab

Platelet function
typically returns to
normal 24-48 hours after
infusion ceases

Excretion

- Renal and faecal elimination

Platelet function
typically returns to
normal 24-48 hours after
infusion ceases

Half-life

- T1/2b 7 hours parent drug (30mins metab) Dur: life of platelet

—
Adverse Effects Toxicity

Bleeding
TTP
Agranulocytosis, Neutropenia
Significant drug interactions as requires activation by CYP450

Haemorrhage, thrombocytopenia, human antichimeric antibody development, allergic reaction

Class Group

Antiplatelet

Antiplatelet

Introduction

ADP Receptor Antagonist - Thienopyridine

GP IIb/IIIA Inhibitor

Legacy Cicm Level

Level 3

Level 3

Main Action

Platelet inhibition

Platelet inhibition